MSLN and cancer: Current MSLN‐targeted therapeutic strategies encompass a range of approaches, including chimeric monoclonal antibodies (such as amatuximab), antibody‐drug conjugates (ADCs; such as anetumab ravtansine [AR], BMS‐986148, and BAY2287411), immunotoxins (such as SS1P and LMB‐100), cancer vaccines (such as the Listeria‐based vaccine expressing MSLN), and CAR T‐cell immunotherapy [238].